We are doing this study to find out if an experimental drug called Lutetium Lu 177 dotatate (the study drug) has the potential to shrink or stabilize bronchial neuroendocrine tumors. We will compare how the study drug works to everolimus, which is the usual drug used for this diagnosis.

Advanced Bronchial Neuroendocrine Cancer

Adults ages 18+ who:

• Are diagnosed with a bronchial neuroendocrine tumor
• Have never been treated with peptide receptor radionuclide therapy (PRRT)
• Have never been treated with mammalian target of rapamycin (mTOR) inhibitors (for example: deforolimus, everolimus, sirolimus, or temsirolimus)

For more information, contact the study team at nick.jeffries@duke.edu.

If you choose to join this study, you will get a random assignment (like a coin flip) to 1 of 2 groups:

• Group1: If you are in this group, you will get the study drug through a vein in the arm every 8 weeks. You will get up to 4 doses of the study drug.
• Group2: If you are in this group, you will get the usual drug, everolimus, as a tablet you take by mouth every day.